Ngā hua rapu kaituhi

1

Eight years experience using the inferior epigastric artery for myocardial revascularization mā L. Puig

I whakaputaina 1997

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
2

Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis mā L. Puig

I whakaputaina 2017

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
3

Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic mā Tiago Torres, L. Puig

I whakaputaina 2020

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
4

Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease mā Helena Iznardo, L. Puig

I whakaputaina 2021

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
5

Dual inhibition of IL-17A and IL-17F in psoriatic disease mā Helena Iznardo, L. Puig

I whakaputaina 2021

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
6

Pathophysiology of Generalized Pustular Psoriasis mā Slaheddine Marrakchi, L. Puig

I whakaputaina 2022

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
7

IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications mā Helena Iznardo, L. Puig

I whakaputaina 2022

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
8

Tyk2 Targeting in Immune-Mediated Inflammatory Diseases mā Lluís Rusiñol, L. Puig

I whakaputaina 2023

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
9

Multi-Omics Approach to Improved Diagnosis and Treatment of Atopic Dermatitis and Psoriasis mā Lluís Rusiñol, L. Puig

I whakaputaina 2024

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
10

Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies mā Guillermo Sánchez-Rodríguez, L. Puig

I whakaputaina 2023

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
11

Genetic and Epigenetic Mechanisms of Psoriasis mā Laura Mateu Arrom, L. Puig

I whakaputaina 2023

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
12

Expression and function of APP and its metabolites outside the central nervous system mā Kendra L. Puig, Colin K. Combs

I whakaputaina 2012

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
13

Treatment Options and Goals for Patients with Generalized Pustular Psoriasis mā James G. Krueger, L. Puig, Diamant Thaçi

I whakaputaina 2022

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
14

Deucravacitinib for the Treatment of Psoriatic Disease mā Ana Maria Lé, L. Puig, Tiago Torres

I whakaputaina 2022

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
15

New and Emerging Biological and Oral/Topical Small-Molecule Treatments for Psoriasis mā Elena Carmona‐Rocha, Lluís Rusiñol, L. Puig

I whakaputaina 2024

Whiwhi kuputuhi katoa
Pré-impressão

Tiaki ki tētahi rārangi

I tiakina i:
16

New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis mā Elena Carmona‐Rocha, Lluís Rusiñol, L. Puig

I whakaputaina 2024

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
17

Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology mā Elena Carmona‐Rocha, Lluís Rusiñol, L. Puig

I whakaputaina 2025

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
18

Pomegranate Polyphenols and Extract Inhibit Nuclear Factor of Activated T-Cell Activity and Microglial Activation In Vitro and in a Transgenic Mouse Model of Alzheimer Disease mā Lalida Rojanathammanee, Kendra L. Puig, Colin K. Combs

I whakaputaina 2013

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Artigo

Tiaki ki tētahi rārangi

I tiakina i:
19

Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis mā Helena Iznardo, Esther Roé, E. Serra‐Baldrich, L. Puig

I whakaputaina 2023

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:
20

Clear or almost clear skin improves the quality of life in patients with moderate‐to‐severe psoriasis: a systematic review and meta‐analysis mā L. Puig, Howard Thom, Patrick Mollon, Hongqing Tian, G.S. Ramakrishna

I whakaputaina 2016

Whiwhi kuputuhi katoa
Revisão

Tiaki ki tētahi rārangi

I tiakina i:

Ngā hua rapu - L. Puig

Eight years experience using the inferior epigastric artery for myocardial revascularization mā L. Puig

Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis mā L. Puig

Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic mā Tiago Torres, L. Puig

Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease mā Helena Iznardo, L. Puig

Dual inhibition of IL-17A and IL-17F in psoriatic disease mā Helena Iznardo, L. Puig

Pathophysiology of Generalized Pustular Psoriasis mā Slaheddine Marrakchi, L. Puig

IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications mā Helena Iznardo, L. Puig

Tyk2 Targeting in Immune-Mediated Inflammatory Diseases mā Lluís Rusiñol, L. Puig

Multi-Omics Approach to Improved Diagnosis and Treatment of Atopic Dermatitis and Psoriasis mā Lluís Rusiñol, L. Puig

Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies mā Guillermo Sánchez-Rodríguez, L. Puig

Genetic and Epigenetic Mechanisms of Psoriasis mā Laura Mateu Arrom, L. Puig

Expression and function of APP and its metabolites outside the central nervous system mā Kendra L. Puig, Colin K. Combs

Treatment Options and Goals for Patients with Generalized Pustular Psoriasis mā James G. Krueger, L. Puig, Diamant Thaçi

Deucravacitinib for the Treatment of Psoriatic Disease mā Ana Maria Lé, L. Puig, Tiago Torres

New and Emerging Biological and Oral/Topical Small-Molecule Treatments for Psoriasis mā Elena Carmona‐Rocha, Lluís Rusiñol, L. Puig

New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis mā Elena Carmona‐Rocha, Lluís Rusiñol, L. Puig

Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology mā Elena Carmona‐Rocha, Lluís Rusiñol, L. Puig

Pomegranate Polyphenols and Extract Inhibit Nuclear Factor of Activated T-Cell Activity and Microglial Activation In Vitro and in a Transgenic Mouse Model of Alzheimer Disease mā Lalida Rojanathammanee, Kendra L. Puig, Colin K. Combs

Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis mā Helena Iznardo, Esther Roé, E. Serra‐Baldrich, L. Puig

Clear or almost clear skin improves the quality of life in patients with moderate‐to‐severe psoriasis: a systematic review and meta‐analysis mā L. Puig, Howard Thom, Patrick Mollon, Hongqing Tian, G.S. Ramakrishna

Ngā utauta rapu:

Ngā marau whai pānga